Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has
Key Highlights: Manufacturing and Testing of MagSense® HER2 Imaging Agent Completed, Paving Way for IND Submission Q1 2026 Wayne State University Collaboration for MRI Optimization
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2
The Market Bull recently invited Imagion Biosystems’ Ward Detwiler and Wayne State University’s Dr. Mark Haacke on the podcast to discuss how molecular MRI and
We are excited to announce that Imagion Biosystems (ASX: IBX) will be attending two premier medical conferences this fall: the Radiological Society of North
FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and
Key Highlights: Positive Feedback from FDA Supports Company’s Plans to File an IND in Q4 2025 Wayne State University Collaboration in MRI adds to existing
Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,